(ASTX727-01) A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Description: 
Study ASTX727-01 will consist of two stages: a Dose Escalation Stage and a Dose Confirmation Stage. The Dose Confirmation Stage consists of 2 parts; the first part is randomized and the second part is an open label expansion.
Study Number: 

PH 267415

Phase: 
Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02103478

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.